Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University led have uncovered how targeted lung cancer drugs alter the shape and behavior of a ...

What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options? When Daniel Wilson, a then-34-year-old father and husband ...

The goal is to find cures for ALK- positive lung cancer by targeting residual disease that remains after initial treatment. ALK Positive was founded on the principle that funding innovative, ...

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the agency announced on Wednesday.

In 5-year follow-up data from the phase III CROWN trial of ALK-positive advanced non-small cell lung cancer (NSCLC), patients receiving lorlatinib (Lorbrena) had the longest progression-free survival ...

Alecensa achieved a 4-year OS rate of 98.4% in resected ALK-positive early-stage NSCLC, outperforming chemotherapy. The ALINA study showed a 65% reduction in disease recurrence or death risk with ...

AUSTIN, Texas , Oct. 24, 2024 /PRNewswire/ -- Genprex, Inc. (GNPX) ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...

A clinical pathway blends expertise from many providers. The primary goal of a clinical pathway is to produce maximum value at each practice site. Dr Konduri’s institution strongly emphasizes the ...

About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the primary analysis of the Phase III ALINA study ...